Creative Planning’s Arcturus Therapeutics ARCT Stock Holding History

Creative Planning’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-45,237	Closed	-$1.87M	–	2092
2021 Q1	$1.87M	Buy	45,237 +1,009	+2%	+$60.1K	﹤0.01%	761
2020 Q4	$1.92M	Sell	44,228 -30	-0.1%	-$2.03K	﹤0.01%	684
2020 Q3	$1.9M	Buy	44,258 +1,968	+5%	+$97.7K	0.01%	586
2020 Q2	$1.98M	Sell	42,290 -12,958	-23%	-$447K	0.01%	502
2020 Q1	$751K	Sell	55,248 -5,723	-9%	-$73.2K	﹤0.01%	755
2019 Q4	$663K	Hold	60,971	–	–	﹤0.01%	971
2019 Q3	$626K	Hold	60,971	–	–	﹤0.01%	953
2019 Q2	$576K	Hold	60,971	–	–	﹤0.01%	1001
2019 Q1	$416K	Buy	+60,971	New	+$312K	﹤0.01%	1135
2014 Q4	–	Sell	-29	Closed	-$3K	–	4140
2014 Q3	$3K	Buy	+29	New	+$3.78K	﹤0.01%	3493

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

Creative Planning's ARCT Position: Q2 2021 in Review

Creative Planning sold out of Arcturus Therapeutics (ARCT) in Q2 2021, closing a stake of 45,237 shares — an estimated $1.87M sold.

Creative Planning first reported a position in ARCT in Q3 2014 and held it in 10 quarters. The position peaked at $1.98M in Q2 2020. 139 funds tracked by Wall St. Rank hold ARCT as of Q2 2021.

Creative Planning reported no remaining Arcturus Therapeutics position as of Q2 2021 after selling out during the quarter.
Creative Planning sold 45,237 Arcturus Therapeutics shares in Q2 2021, an estimated $1.87M.
Creative Planning first reported a position in Arcturus Therapeutics in Q3 2014 and held it in 10 quarters.
Creative Planning's Arcturus Therapeutics position peaked at $1.98M in Q2 2020.
139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2021.

Based on Creative Planning's 13F filing for Q2 2021, filed 4 Aug 2021.